drugset / Trial / NCT01128842

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

NCT01128842

Phase 1 Completed 7 enrolled Puma Biotechnology, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, phase 1 study of a single cohort of neratinib (HKI-272) in combination with capecitabine.

Timeline

Start
2010-04
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1500 mg/m2 Oral
Subject Neratinib Small molecule 240 mg Oral

Indications